drugset / Trial / NCT00383487

A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

NCT00383487

Phase 2 Terminated 20 enrolled Stanford University Novacea · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.

Timeline

Start
2005-03
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcitriol Small molecule 0.5 ug/kg
Subject naproxcinod Other / unclassified 400 mg Oral

Indications